Skip to main content
Equibles

Lishan Aklog

CEO

PAVmed Inc. (PAVM)

CEO

Lucid Diagnostics Inc. (LUCD)

Equibles does not estimate personal net worth.

Get an email with a short summary when PAVmed Inc. publishes a filing, an earnings call transcript or a press release.

Get PAVM alerts

About Lishan Aklog

Lishan Aklog is recorded as CEO at PAVmed Inc. (PAVM) and CEO at Lucid Diagnostics Inc. (LUCD). The newest filing on record that lists Lishan Aklog as CEO at PAVmed Inc. (PAVM) is dated April 30, 2026. The newest filing on record that lists Lishan Aklog as CEO at Lucid Diagnostics Inc. (LUCD) is dated April 30, 2026. The proxy statement of Lucid Diagnostics Inc. reports total compensation of $897,000 for Lishan Aklog in fiscal 2025, including a base salary of $300,000. Disclosed compensation is on record for 7 fiscal years. Lishan Aklog has spoken on 36 earnings calls and 2 other investor events across 2 companies, most recently for PAVmed Inc. on August 14, 2026. Those appearances were for PAVmed Inc. (PAVM) and Lucid Diagnostics Inc. (LUCD). PAVmed Inc. is classified in the Medical Devices industry within the Healthcare sector. Lucid Diagnostics Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at PAVmed Inc. includes Michael J. Glennon (Chairman and Board Member), Dennis McGrath (CFO), Shaun M. O’Neil (COO) and 7 others.

Lishan Aklog on recent calls

“Well, so we're seeing tangible progress across each of our core businesses. Lucid continues to advance key reimbursement and commercialization initiatives.”
CEO, PAVmed Inc. Q2 FY2026 Earnings Call ·
“Good morning everyone thank you for joining us today and for your continued engagement and support. We continue to make strong progress across key personalization initiatives as we await Medicare draft LTV publication and we're eager to discuss these today.”
CEO, Lucid Diagnostics Inc. Q2 FY2026 Earnings Call ·
“So Lucid Diagnostics is a cancer prevention company. We're in the esophageal cancer space. Esophageal cancer is a very deadly cancer. It's the second most deadly cancer, highly lethal.”
CEO, Canaccord Genuity 46th Annual Growth Conference ·
“At our last business update call, we discussed the two-year process we undertook to permanently fix PadMed's legacy capital structure and strengthen its balance sheet.”
CEO, PAVmed Inc. Q1 FY2026 Earnings Call ·
“So let's begin with some key highlights from the first quarter and we performed $3,177 each year and generated revenue at one point slightly, but proportional to volume, which received a bit but remained above our target.”
CEO, Lucid Diagnostics Inc. Q1 FY2026 Earnings Call ·

Affiliation history

Company network

Leadership on record at PAVmed Inc.

Leadership on record at Lucid Diagnostics Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Lucid Diagnostics Inc. (LUCD) $300,000 $897,000
2024 PAVmed Inc. (PAVM) $913,000 $1,365,200
2024 Lucid Diagnostics Inc. (LUCD) $300,000 $712,000
2023 PAVmed Inc. (PAVM) $913,000 $953,200
2023 Lucid Diagnostics Inc. (LUCD) $300,000 $300,000
2022 PAVmed Inc. (PAVM) $900,500 $1,634,791
2022 Lucid Diagnostics Inc. (LUCD) — $455,700
2021 PAVmed Inc. (PAVM) $582,667 $9,261,677
2021 Lucid Diagnostics Inc. (LUCD) — $7,280,760
2020 PAVmed Inc. (PAVM) $431,000 $1,196,300
2020 Lucid Diagnostics Inc. (LUCD) — —
2019 PAVmed Inc. (PAVM) $431,000 $889,850

Recent activity

Show 26 earlier activities